Gene single nucleotide polymorphism accumulation improves survival in advanced head and neck cancer patients treated with weekly paclitaxel

✍ Scribed by Juan J. Grau; Miguel Caballero; Marc Campayo; Sonia Jansa; Mauricio Vargas; Llucia Alós; Mariano Monzo

• Publisher: John Wiley and Sons
• Year: 2009
• Tongue: English
• Weight: 108 KB
• Volume: 119
• Category: Article
• ISSN: 0023-852X
• DOI: 10.1002/lary.20254

✦ Synopsis

Abstract

Objectives/Hypothesis:

Single nucleotide polymorphisms (SNPs) of certain genes involved in drug metabolism correlate with survival.

Methods:

We evaluated the presence of SNPs in six genes (CYP2C8, GSTT1, GSTP1, MDR1‐57, MDR1‐62, and ERCC1) and the response rate (RR), time to progression (TTP), and overall survival (OS) of advanced head and neck cancer patients treated with weekly paclitaxel.

Results:

SNPs in CYP2C8, MDR1‐57, and MDR1‐62 genes were more frequent than wild‐type genes in our patients. RR was 45% (21/47), and median TTP in responders was 5.1 months. OS for all patients was 5.6 months. Response was higher in SNPs of MDR1‐62, MDR1‐57, or in two or more accumulated genes than in those with wild‐type genes. OS was significantly longer in patients with two or more accumulated SNPs (P = .039).

Conclusions:

Response rate and OS were significantly higher in patients with two or more accumulated SNPs. Laryngoscope, 2009